| oxaliplatin / Generic mfg. |
NCT01286818: A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) |
|
|
| Completed | 1b | 6 | Japan | Ramucirumab (IMC-1121B), IMC-1121B, Ramucirumab, LY3009806, Irinotecan, levofolinate, 5-Fluorouracil (5-FU) | Eli Lilly and Company | Colorectal Carcinoma | 02/12 | 03/12 | | |
|
NCT00660153: Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers |
|
|
| Completed | 1b | 30 | Europe | Tivozanib (AV-951) plus FOLFOX6 | AVEO Pharmaceuticals, Inc. | Colorectal Cancer, Gastrointestinal Cancer | 06/12 | 06/12 | | |
|
NCT02359058: A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer |
|
|
| Completed | 1b | 18 | Japan | Ramucirumab, LY3009806, IMC-1121B, Capecitabine, Cisplatin, S-1, Oxaliplatin | Eli Lilly and Company | Stomach Neoplasms | 07/16 | 11/16 | | |
NCT02069041: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer |
|
|
| Completed | 1b | 8 | RoW | Ramucirumab, IMC-1121B, LY3009806, FOLFOX4, FOLFOX4 (leucovorin + fluorouracil + oxaliplatin) | Eli Lilly and Company | Carcinoma, Hepatocellular | 09/16 | 09/16 | | |
| Completed | 1 | 18 | RoW | ZD6474 (vandetanib), ZACTIMA™, 5-Fluorouracil, 5-FU, Leucovorin, Oxaliplatin | Genzyme, a Sanofi Company | Advanced Colorectal Carcinoma | 06/06 | 04/08 | | |
NCT00353262: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 1 | 36 | Canada | Avastin, Oxaliplatin, capecitabine [Xeloda] | Hoffmann-La Roche | Colorectal Cancer | 09/06 | 04/08 | | |
NCT00300027: Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies |
|
|
| Terminated | 1 | 50 | US | BMS-582664 | Bristol-Myers Squibb | Gastrointestinal Neoplasms | 12/06 | | | |
NCT00403052: A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Terminated | 1 | 14 | US | 1018 ISS immunostimulatory oligonucleotide | Dynavax Technologies Corporation | Colorectal Neoplasms | 12/07 | 12/07 | | |
NCT00599924: Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors |
|
|
| Completed | 1 | 53 | US | sunitinib + FOLFOX, Sunitinib malate, SUTENT, mFOLFOX6 | Pfizer | Colorectal Neoplasms, Neoplasms | 11/08 | 11/08 | | |
|
NCT00631410: Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer |
|
|
| Completed | 1 | 12 | Japan | sunitinib + mFOLFOX6 | Pfizer | Colorectal Neoplasms | 07/09 | 03/10 | | |
|
NCT01271166: Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer |
|
|
| Terminated | 1 | 10 | RoW | Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab | Novartis Pharmaceuticals | Advanced Colorectal Cancer | 08/09 | | | |
NCT00220649: Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas |
|
|
| Completed | 1 | 25 | US | gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin | St. Luke's-Roosevelt Hospital Center, Sanofi | Pancreatic Neoplasms | | | | |
NCT00387387: Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) |
|
|
| Completed | 1 | 50 | Europe, RoW | Pazopanib, FOLFOX 6, CapeOx | GlaxoSmithKline | Neoplasms, Colorectal | 08/09 | 08/09 | | |
NCT00478634: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 19 | US | RAD001, Cetuximab, Irinotecan | Novartis Pharmaceuticals | Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal | 09/09 | 09/09 | | |
NCT00101894: Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 119 | US | FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI | Amgen | Rectal Cancer, Colon Cancer | 04/10 | 12/11 | | |
|
NCT00532909: Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 13 | US | Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab | Branimir Sikic, AstraZeneca | Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer | 05/10 | 05/10 | | |
NCT00920868: XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib |
|
|
| Completed | 1 | 22 | US | dasatinib, Sprycel, bevacizumab, Avastin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Herbert Hurwitz, MD, Bristol-Myers Squibb | Solid Tumor, Metastatic Colorectal Cancer | 05/10 | 08/14 | | |
NCT00555620: Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer |
|
|
| Completed | 1 | 76 | RoW | capecitabine, oxaliplatin, sunitinib malate, Sutent, cisplatin | Pfizer | Stomach Neoplasms | 08/10 | 12/11 | | |
|
NCT00779311: A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer |
|
|
| Terminated | 1 | 8 | US | sorafenib, Nexavar, bevacizumab, Avastin, mFOLFOX6 regimen | Accelerated Community Oncology Research Network, Bayer | Metastatic Colorectal Cancer | 03/11 | 03/11 | | |
NCT00861783: Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma |
|
|
| Completed | 1 | 16 | US | irinotecan and ON 01910.Na, camptothecin-11, irinotecan HCl, Camptosar, CPT-11, diaminocyclohexane oxalatoplatinum, rigosertib sodium, oxaliplatin and ON 01910.Na, Eloxatin, oxaloplatinum, oxalatoplatin | Onconova Therapeutics, Inc. | Hepatoma, Advanced Solid Tumor | 07/11 | 07/11 | | |
| Completed | 1 | 10 | US | Oxaliplatin | David Bartlett, The Pittsburgh Foundation, Sanofi | Unresectable Colorectal Liver Metastases | 11/11 | 11/11 | | |
NCT02720926: Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer |
|
|
| Terminated | 1 | 3 | RoW | Xeloda,, capecitabine, Oxaliplatin, TKI258 | National Cancer Centre, Singapore, Novartis | Colorectal Cancer, Gastric Cancer | 01/12 | 01/12 | | |
NCT00934882: Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI |
|
|
| Completed | 1 | 45 | Europe | Regorafenib (BAY73-4506) | Bayer | Colorectal Neoplasms | 04/12 | 04/12 | | |
|
|
NCT00940758: Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy |
|
|
| Completed | 1 | 18 | RoW | PEP02 | PharmaEngine | Metastatic Colorectal Cancer | 05/12 | 06/14 | | |
NCT01383538: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma |
|
|
| Completed | 1 | 15 | US | FOLFIRINOX, IPI-926, Oxaliplatin, Leucovorin, Irinotecan, 5-FU | Andrew Ko, Infinity Pharmaceuticals, Inc. | Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms | 12/12 | 05/15 | | |
|
NCT00879385: KRAS Wild-type Metastatic Colorectal Cancer Trial |
|
|
| Completed | 1 | 21 | US | Dacogen™ (decitabine), Vectibix® (panitumumab) | University of Utah, Amgen, Eisai Inc. | Colorectal Cancer | 01/13 | 01/13 | | |
|
NCT01693445: S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer |
|
|
| Completed | 1 | 22 | RoW | OIS (Oxaliplatin, Irinotecan, S-1), Kabioxaliplatin, Campto, TS-1 | Hallym University Medical Center, Jeil Pharmaceutical Co., Ltd., HK inno.N Corporation, Pfizer, Handok Inc. | Gastrointestinal Neoplasms | 02/14 | 08/14 | | |
VEOX, NCT01386346: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer |
|
|
| Completed | 1 | 12 | US | Azacitidine, Vidaza®, 5-Azacitidine, Oxaliplatin, Eloxatin, Epirubicin, Ellence, Capecitabine, Xeolda | Weill Medical College of Cornell University, Celgene Corporation | Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach | 08/14 | 09/18 | | |
NCT01764477: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma |
|
|
| Completed | 1 | 20 | US | PRI-724 | Prism Pharma Co., Ltd., inVentiv Health Clinical | Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma | 10/15 | 10/15 | | |
NCT02268825: Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers |
|
|
| Terminated | 1 | 39 | US | MK-3475 | University of Utah, Merck Sharp & Dohme LLC | Advanced GI Cancer | 01/17 | 06/17 | | |
NCT02041481: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 26 | US | MEK inhibitor MEK162, ARRY-162, ARRY-438162, Binimetinib, MEK inhibitor ARRY-438162, MEK162, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies, Laboratory Biomarker Analysis | City of Hope Medical Center, National Cancer Institute (NCI), Array BioPharma | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 01/18 | 01/18 | | |
|
